https://ivmmeta.com/#fig_fpp

#ivm #ivermectin #therapeutics #earlytreatment

https://clinicaltrials.gov/ct2/show/NCT04425863

#ivermectin #ivm #therapeutics #earlytreatment

QUERCETIN https://c19quercetin.com/qmeta.html

#quercetin #therapeutics #earlytreatment

https://c19vitamind.com/

#vitd #therapeutics #earlytreatment

now compare with Remdesivir

https://c19rmd.com/smeta.html

#remdesivir

https://c19melatonin.com/jmeta.html

#melatonin #therapeutics #earlytreatment

#video #CMSdata #vaccinedeaths

N-Acetylcysteine, #NAC #earlytreatment #therapeutics

Inhalation of Vapor with Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients – A Case Control Study

N-Acetylcysteine to Combat COVID-19: An Evidence Review

N-acetyl cysteine: A tool to perturb SARS-CoV-2 spike protein conformation

N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence

N-Acetylcysteine to Combat COVID-19: An Evidence Review

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial

N-acetylcysteine: A rapid review of the evidence for effectiveness in treating COVID-19

A Study of N-acetylcysteine in Patients with COVID19 Infection

N-acetylcysteine as a potential treatment for COVID-19

N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019

Case Report: Use of hydroxychloroquine and N-acetylcysteine for treatment of a COVID-19 patient [version 2; peer review: 2 not approved]

Studies show N-Acetyl Cysteine supplement can possibly protect patients against COVID-19

Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19

Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial

N-acetylcysteine in Severe COVID-19: The Possible Mechanism

Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence

Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19

https://c19hcq.com/

#HCQ #Hydroxychloroquine #earlytreatment #therapeutrics #prophylaxis

The FDA has ordered Pfizer to perform studies on the side effects of their bioagent "vaccine" on children's hearts (Myocarditis).

THE STUDIES WILL BE COMPLETED IN MAY 2027.

2027.

Yet they're going to "vaccinate" kids in meantime.

SOURCE: (pg 8)

Del Bigtree, from The High Wire, issues a dire warning to the world as he discusses the legitimate concern of Antibody Dependent Enhancement (ADE) with COVID-19 'investigational vaccines' and the implications of a worldwide 'vaccine' rollout amongst the global populace without proper clinical trials to study the long-term effects of mRNA vaccine technology.

additional ADE resources:
[01], [02], [03], [04], [05], [06], [07]

#DelBigtree #video

"On these bases, a study was planned in 30 COVID19-infected patients with initial or important symptomatology, 16 of whom orally treated by MLT (20 mg/day in the evening) plus cannabidiol (CBD) (10 mg x 2/day) only, while the other 14 patients received also Ang 1-7 (0.5 mg 2/day orally). The results were compared to those observed in a control group of 30 COVID-19 infected patient, who received the only supportive therapy. No hospitalisation for initial respiratory failure was required in the group of patients treated by the neuroimmune regimen. In addition, most patients referred a rapid disappearance of fever and myalgia, as well as a relief of asthenia, particularly in those concomitantly treated with Ang 1-7. On the contrary, 5/30 (17%) control patients required hospitalisation. The difference was statistically significant (0/30 vs 5/30, P< 0.05). This preliminary study would suggest that a neuroimmune approach consisting of MLT and CBD in association with Ang 1-7 is an effective and non-toxic regimen in the therapy of COVID19-related symptoms, which could also control the clinical evolution of disease and reduce the need of hospitalisation."